Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb;33(1):26-38.
doi: 10.1111/tme.12942. Epub 2022 Nov 22.

A systematic review of the safety and efficacy of convalescent plasma or immunoglobulin treatment for people with severe respiratory viral infections due to coronaviruses or influenza

Catherine Kimber  1   2 , Abigail A Lamikanra  2   3 , Louise J Geneen  1   2 , Josie Sandercock  1   2 , Carolyn Dorée  1   2 , Sarah J Valk  2   4 , Lise J Estcourt  1   2   5
Affiliations

A systematic review of the safety and efficacy of convalescent plasma or immunoglobulin treatment for people with severe respiratory viral infections due to coronaviruses or influenza

Catherine Kimber et al. Transfus Med. 2023 Feb.

Abstract

Objective: Evaluate the safety and effectiveness of convalescent plasma (CP) or hyperimmune immunoglobulin (hIVIG) in severe respiratory disease caused by coronaviruses or influenza, in patients of all ages requiring hospital admission.

Methods: We searched multiple electronic databases for all publications to 12th October 2020, and RCTs only to 28th June 2021. Two reviewers screened, extracted, and analysed data. We used Cochrane ROB (Risk of Bias)1 for RCTs, ROBINS-I for non-RCTs, and GRADE to assess the certainty of the evidence.

Results: Data from 30 RCTs and 2 non-RCTs showed no overall difference between groups for all-cause mortality and adverse events in four comparisons. Certainty of the evidence was downgraded for high ROB and imprecision. (1) CP versus standard care (SoC) (20 RCTS, 2 non-RCTs, very-low to moderate-high certainty); (2) CP versus biologically active control (6 RCTs, very-low certainty); (3) hIVIG versus SoC (3 RCTs, very-low certainty); (4) early CP versus deferred CP (1 RCT, very-low certainty). Subgrouping by titre improved precision in one outcome (30-day mortality) for the 'COVID high-titre' category in Comparison 1 (no difference, high certainty) and Comparison 2 (favours CP, very-low certainty). Post hoc analysis suggests a possible benefit of CP in patients testing negative for antibodies at baseline, compared with those testing positive.

Conclusion: A minimum titre should be established and ensured for a positive biological response to the therapy. Further research on the impact of CP/hIVIG in patients who have not yet produced antibodies to the virus would be useful to target therapies at groups who will potentially benefit the most.

Keywords: convalescent; hyper-immune immunoglobulin; infection; plasma; respiratory; safety.

PubMed Disclaimer

References

REFERENCES

    1. WHO Coronavirus (COVID-19) Dashboard. World Health Organisation (WHO) Emergency Dashboard. 2022. Accessed May 19, 2022. https://covid19.who.int/
    1. Sun J, Zheng Q, Madhira V, et al. Association between immune dysfunction and COVID-19 breakthrough infection after SARS-CoV-2 vaccination in the US. JAMA Int Med. 2022;182(2):153-162.
    1. Recovery CG. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet. 2021;397(10289):2049-2059.
    1. ACTIV-3. Therapeutics for inpatients with COVID-19 (TICO). Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial. Lancet Infect Dis. 2021;22:622-635.
    1. Wellcome and IAVI. Expanding Access to Monoclonal Antibody-Based Products: a Global Call to Action. 2020. https://wellcome.org/reports/expanding-access-monoclonal-antibodies.

Publication types

Substances

LinkOut - more resources